Eiger Biopharmaceuticals Inc (EIGR)

NASDAQ
6.520
-0.040(-0.61%)
After Hours
6.520
0.000(0.00%)
- Real-time Data
  • Volume:
    94,594
  • Bid/Ask:
    6.210/7.500
  • Day's Range:
    6.260 - 6.615

EIGR Overview

Prev. Close
6.56
Day's Range
6.26-6.615
Revenue
8.79M
Open
6.37
52 wk Range
5.82-13.49
EPS
-0.94
Volume
94,594
Market Cap
221.52M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
175,900
P/E Ratio
-
Beta
1.29
1-Year Change
-29.13%
Shares Outstanding
33,975,800
Next Earnings Date
Mar 17, 2022
What is your sentiment on Eiger Biopharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Eiger Biopharmaceuticals Inc Company Profile

Employees
34

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.